IDH1 and glioma: To highlight novel proteins that can robustly distinguish BrM from glioma beyond the existing IHC biomarkers, we linked those dysregulated proteins and phosphosites to clinical parameters using the weighted gene co‐expression network analysis (WGCNA) algorithm.[34] A linear model was constructed, considering age, sex, group, subtype, WHO grade, IDH1 status, Ki67 score, and IHC markers staining score as control variables (Table S3, Supporting Information).